Our study provides a simple and feasible predictive model for ORR in patients with resectable locally advanced esophageal cancer after neoadjuvant TP regimen combined PD-1 inhibitors, which might be used in clinical practice for clinicians. This evidence concerns the gene PDCD1 and esophageal cancer.